|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||112.47 - 114.00|
|52 Week Range||81.12 - 121.75|
|PE Ratio (TTM)||37.47|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.
Medtronic's (MDT) CVG arm continues to be the highest revenue grossing segment. Thus, the company's CE Mark receipt for Attain Stability Quad MRI SureScan Active-Fixation heart lead buoys optimism.
PerkinElmer's (PKI) expanding product portfolio helps it gain global market share. However, the company's regular acquisitions pose integration risks.